Myelotoxicity is a dose-limiting effect of many chemotherapeutic regimens. Thus, there is great interest in protecting human hematopoietic stem cells by the transfer of drug resistance genes. The main focus of this study was the simultaneous overexpression of multidrug resistance 1 (MDR1) and the O 
Introduction
Cancer chemotherapy is often associated with toxicity towards the hematopoietic system resulting in myelosuppression. Several gene therapy approaches to protect hematopoietic cells against toxicity of chemotherapeutic drugs have been developed in the last few years. Protection against myelosuppression by transfer of drug-resistance genes to hematopoietic (CD34 + ) stem cells has been demonstrated clearly in numerous animal models. The proposed clinical setting is the transplantation of ex vivo transduced CD34 + cells after conditioning therapy. Subsequently the patients should receive further sequential dose-intense chemotherapy, which would not be possible after simple CD34 + cell transplantation. The unmodified hematopoiesis would be too frail to sustain the stress of further chemotherapy, whereas a genemodified hematopoiesis is expected to survive this toxic stress. The reduction of toxic side-effects especially of myelosuppression after chemotherapy may allow for the use of more dose-intense drug combinations designed to ultimately overcome tumor resistance.
Overexpression of the multidrug resistance 1 (MDR1) or O 6 -methylguanine-DNA methyltransferase (MGMT) genes has been shown to protect hematopoietic stem cells. Overexpression of MGMT in hematopoietic stem cells is of special interest, because therein the level of endogenous MGMT is low. 1 Although MDR1 is endogenously expressed in human CD34 + cells, the expression is silenced in differentiated myeloid cells. 2, 3 Therefore, overexpression of MDR1 in hematopoietic stem cells will also be of interest to protect the differentiated lineages. The human MDR1 gene encodes the ABCB1-transporter, a member of the ATP-binding cassette superfamily, and confers resistance to a wide array of cytostatic agents like doxorubicin, etoposide, vincristine and paclitaxel. 4, 5 Previous findings of our group for the first time indicated that an optimized retroviral vector and transduction protocol resulted in clinically relevant levels of MDR1 gene marking and expression, as well as in chemoprotection of human hematopoiesis in vivo in a NOD/SCID mouse xenotransplantation model. 6 Recently, MDR1 expressing vectors have already been validated in clinical trials for the feasibility of bone-marrow chemoprotection. [7] [8] [9] [10] Chemoresistance conferred by the human MGMT is based on a different mechanism. MGMT removes alkylgroups added to guanine by drugs like 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), thereby preventing crosslinking and serious DNA damage. 11, 12 The transfer of alkyl-adducts to MGMT is a stoichiometric reaction, resulting in an irreversible inactivation of the MGMT molecule and degradation by ubiquitination. 13 [21] [22] [23] This approach was already applied successfully in several in vivo investigations with mice 24, 25 and in a canine model demonstrating that retroviral overexpression of MGMT P140K in blood stem cells prevented myelosuppression associated with combination of O 6 -BG and the alkylating agent temozolomide (TMZ). 26 As in clinical protocols usually drug combinations are used, simultaneous expression of two chemoprotective proteins with different mechanisms of action would be advantageous. In order to be sure that transduced cells will overexpress both genes, it is profitable to use a bicistronic combination vector instead of transducing cells with two monocistronic single vectors. Transduction with two single vectors would require a higher multiplicity of infection (MOI), resulting in a higher risk of insertional mutagenesis and a laborious selection procedure with the respective substrates would be necessary to secure a simultaneous chemoprotective effect of both transgenes.
In a few studies, the combination of MDR1 and wild-type MGMT vectors have been evaluated for their chemoprotective potential against different substances. [27] [28] [29] Only once the MGMT P140K mutant was used. 30 Furthermore, in only one of the other studies with a retroviral bicistronic vector containing MDR1 and MGMT transduction of human CD34 + cells was done. 29 The use of these cells is of special clinical relevance in terms of a future application of a chemoprotective gene therapy. However, in all of these in vitro approaches gammaretroviral vectors were applied. For efficient gene transfer into non-dividing cells like hematopoietic stem cells, the use of lentiviral vectors would be advantageous.
31,32
Therefore, we have chosen a lentiviral SIN vector of the third generation 32, 33 for co-expression of both the transgenes MDR1 and MGMT P140K , linked by an EMCV-IRES element (internal ribosome entry site from encephalomyocarditis virus). HL60 (myeloid leukemia cell line) and human hematopoietic stem cells (CD34   +   )  were transduced with this combination vector (HR'SIN-MDR1-IRES-MGMT   P140K   ) or as controls with singlegene vectors containing either MDR1 or MGMT P140K as transgene. Subsequently single or combination therapies with 1-(2-chloroethyl)-3-(4-amino-2-methylpyrimidine-5-yl)methyl-1-nitrosourea) (ACNU) or TMZ and paclitaxel or BCNU and doxorubicin were carried out. P140K was 3.6-fold higher compared with cells transduced with the combination vector. This result is not very surprising since IRES-dependent expression of the second cistron in a bicistronic expression cassette was shown to reach only 10-50% of the expression level of the first cistron. 34, 35 Regarding MDR1 expression no difference was detectable between combination and single vector (1.1-fold). -overexpression by the combination vector in the myeloid leukemia cell line HL60, the main experiments were carried out on primary human hematopoietic stem cells (CD34 + ). The liquid culture proliferation assay in combination with the Rh-123 assay for testing of MDR1-expressing cells was chosen instead of a colony-forming assay, because the proliferation assay is more accurate and shows a lower variability in results. 2 Also Ferlini et al. 36 have evaluated myelotoxicity of doxorubicin and other anti-tumor agents in liquid cultures followed by flow cytometric analysis, and found this assay type suitable for testing chemotherapeutic efficiencies.
Results

Transduction of HL60 cells with lentiviral vectors
After O 6 -BG/BCNU-monotherapy (concentrations of BCNU up to 16 mM) HR'SIN-MGMT P140K transduced cells showed in FACS analysis a significant increase of the proportion of MGMT-positive cells, from 10.1±4.7% (untreated) to 70.9 ± 16.0% (treated with 16 mM BCNU) (difference 60.8±11.7%, P ¼ 0.03 compared with untransduced control with a difference of 9.0 ± 9.6%). Cells transduced with the combination vector HR'SIN-MDR1-IRES-MGMT P140K showed no corresponding increase of MGMT-positive cells after the same treatment (difference 2.0 ± 1.0%) (Figure 2a , Table 2a ).
Treatment with increasing concentrations of doxorubicin up to 0.8 mM resulted in an enrichment of MDR1-overexpressing cells; for cells transduced with HR'SIN-MDR1 the increase was 45.4 ± 14.6% (0 mM: 1.7±0.9%, 0.8 mM: 47.1±15.5%, P ¼ 0.05 compared with untransduced control with a difference of 6.5 ± 2.2%) or with HR'SIN-MDR1-IRES-MGMT P140K 44.9±4.5% (0 mM: 2.1 ± 1.1%, 0.8 mM: 47.0 ± 5.2%, P ¼ 0.05 compared with untransduced control) ( Figure 2b , Table 2b ).
Combination therapy of transduced CD34
+ cells with 
Chemoresistance of transduced CD34
+ cells to O 6 -BG/TMZ and paclitaxel
The experiments with transduced CD34 + cells were also carried out using another clinically used drug combination in monotherapy and combination therapy, that is O 6 -BG/TMZ and paclitaxel. Concerning overexpression of MGMT we found a protective effect for cells transduced with the combination vector for monotherapy with TMZ (0 mM: 1.6 ± 2.1%, 800 mM: 29.9 ± 15.2%, difference: 28.3±16.4%, P ¼ 0.01 compared with untransduced control), for HR'SIN-MGMT P140K transduced cells the difference was 57.5±7.9% (0 mM: 17.5±6.4%, 800 mM: 75.0 ± 2.8%, P ¼ 0.03 compared with untransduced control) and for untransduced cells the difference was 2.1 ± 1.8% (Figure 3a, Table 3a) .
The Rh-123 assay showed similar protective effects of the combination vector for monotherapy with paclitaxel (0 mM: 1.2±0.3%, 0.4 mM: 89.8±2.4%, difference: 88.5 ± 2.2%, P ¼ 0.01 compared with untransduced control with a difference of 21.8 ± 4.7%), compared with the MDR1 single vector (0 mM: 3.2 ± 2.8%, 0.4 mM: 93.2 ± 5.9%, difference: 90.0 ± 3.3%, P ¼ 0.01 compared with untransduced control) ( Figure 3b, Table 3b ).
Combination therapy with 400 mM TMZ and 0.4 mM paclitaxel resulted in a higher difference of MGMTpositive cells between treated and untreated cells for the combination vector (0 mM: 0.9±0.3%, 400 mM TMZ/ 0.4 mM paclitaxel: 53.7 ± 13.5%, difference: 52.8 ± 13.8%) than for the MGMT P140K single vector (0 mM: 21.4±2.2%, 400 mM TMZ/0.4 mM paclitaxel: 50.4 ± 4.3%, difference: 29.1±2.1%); for untransduced cells the difference was 9.0 ± 5.2% (Figure 3c, Table 3a) .
Furthermore, the combination vector showed a higher increase in MDR1-positive cells than the MDR1 single vector after combination therapy with 400 mM TMZ and 0.4 mM paclitaxel (HR'SIN-MDR1-IRES-MGMT P140K : 0 mM: 9.9±13.4%, 400 mM TMZ/0.4 mM paclitaxel: 94.5 ± 1.0%, difference: 84.6 ± 13.6%, HR'SIN-MDR1: 0 mM: 9.6±12.0%, 400 mM TMZ/0.4 mM paclitaxel: 79.3 ± 15.7%, difference: 69.7 ± 3.9%); for untransduced cells the difference was 29.8±9.4% (Figure 3d , Table 3b ).
Discussion
Gene therapy with drug-resistance genes is in focus of recent chemoprotection studies of normal cells during tumor chemotherapy. The rational behind this approach is that transplantation of gene therapy-modified blood stem cells before the high-dose chemotherapy would allow more intense or also prolonged chemotherapy with reduced myelotoxicity. This approach would be much more beneficial for the patient in contrast to a normal chemotherapy regimen, wherein the hematopoiesis will be wearing out with time and in contrast to a standard autologous transplant where unmodified CD34 + cells are given after single high-dose chemotherapy. An argument against this approach could be that not only normal CD34 + cells but also circulating tumor cells might be mobilized by granulocyte colony-stimulating factor (G-CSF) for leukapheresis, and thus will also possibly be transduced and transplanted. However, this risk seems to be very low as blood stem cells are selected after leukapheresis for CD34 expression by MACS under clinical GMP/GLP conditions. In BM and PB samples of patients with multiple myeloma could be shown that because of this purification step 99.99% of tumor cells are depleted (log 3.97). 37 For multiple myeloma it could be shown that purged vs un-purged transplants did not result in different disease free or overall survival, 37 The most intense studied genes for chemoprotective gene therapy are MDR1 [6] [7] [8] [9] [10] and MGMT. [24] [25] [26] As drug combinations are common in most chemotherapeutic regimens, gene therapy with a combination of several genes is particularly promising and would increase the therapeutic index of combination chemotherapy.
In this study, clinically relevant combinations of chemotherapeutic drugs were used. BCNU and doxorubicin are administered as treatment of multiple myeloma, 38 ACNU and paclitaxel for non-small cell lung cancer, 39 TMZ and paclitaxel for treatment of malignant melanoma 40 and malignant brain tumors like glioma and medulloblastoma. 41 A severe problem is the development of resistance against alkylating agents by high expression of wild-type In contrast with other studies examining combination gene therapy with MDR1 and MGMT expressed by a gammaretroviral vector, [27] [28] [29] [30] we chose a third generation lentiviral self-inactivating (SIN) vector 32 . Besides the advantageous lentiviral ability of transducing nondividing cells, 32 the risk of vector mobilization and recombination is minimized by the establishment of lentiviral SIN-vectors. 43 These vectors do not contain the terminal repetition of the enhancer/promoter sequences, with the objective of attenuating the interaction with neighbouring cellular genes. The transforming capacity of SIN vectors is significantly reduced when compared with corresponding LTR vectors. 44 In insertion site analyses our group could show that lentiviral vectors in contrast to gammaretroviral vectors integrated at a significantly lower rate within a distance of 10 kb from the transcription start site. 45, 46 Therefore, the probability of affecting oncogenes or tumor suppressor genes might be lower by the use of lentiviral vectors. In a model with tumor-susceptible mice transplantation of gammaretroviral-transduced hematopoietic cells resulted in an accelerated tumorigenic process, whereas with lentiviral vectors no additional adverse events were detected. 47 Comparing gammaretroviral with lentiviral vectors Montini et al. 48 found that 'substantially greater lentiviral integration loads are required to approach the same oncogenic risk as gammaretroviruses'. Lentiviral SINvectors are in use in current clinical gene therapy trials and probably in the near future will gradually replace gammaretroviral vectors. 49 Besides these aspects concerning the safety of vectors, a direct comparison of gammaretroviral and lentiviral SIN-vectors showed no differences regarding the expression of MGMT P140K and the protection levels after exposure to O 6 -BG/BCNU in hematopoietic cells. 50 However, for the clinical use of our bicistronic lentiviral vector more intense safety analyses will be required.
In several pre-clinical and clinical gene therapy studies using retroviral vectors no impairment of longterm hematopoiesis by transduced blood stem cells could be detected. In a rhesus macaque model, our group could show that gammaretrovirally transduced blood stem cells contributed to long-term hematopoiesis on a stable level. 51 The success of several clinical studies which all used retrovirally transduced hematopoietic stem cells, prompted Kohn and Candotti 52 to title their editorial this January in New England Journal of Medicine with 'Gene Therapy Fulfilling its Promise'. In all of these studies (concerning, for example, therapy of sickle-cell disease, b-thalassemia or SCID) the transduced blood stem cells reconstituted successfully the previously distorted hematopoiesis.
We examined the chemoprotective effect of lentiviral MDR1 and MGMT P140K overexpression by using the myeloid leukemia cell line, HL60, and primary human hematopoietic stem cells. Our results clearly demonstrated that the protective effect of the combination vector is comparable with that of the single vector for monotherapy and superior for combination therapy, both gene. IRES-dependent expression is shown to reach only 10-50% of the expression level of the first cistron in a bicistronic vector. 34 Southgate et al. 30 have shown with a retroviral vector containing MDR1 and an IRES-dependent MGMT P140K gene, that the activity of MGMT is 10-fold lower in comparison with a cap-dependent MGMT. In this context it has to be mentioned, that MGMT is not a 'true' enzyme, because it inactivates itself after receiving the alkyl-group from guanine. That means an MGMT molecule can repair only one O 6 -guanine lesion.
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Therefore, the efficiency of repair depends on protein expression. A possible way to overcome the problem of unequal expression of the two genes in a bicistronic vector would be the use of other connecting elements like the FMDV 2A sequence. 53 This approach may lead to a more equimolar expression of both proteins encoded in a bicistronic vector.
The low transduction efficiency of CD34 + cells with HR'SIN-MDR1-IRES-MGMT P140K might be a further explanation for the lower chemoprotective effect against monotherapy with this combination vector than with HR'SIN-MGMT
P140K
. The different transduction efficiency (2.1% vs 10.1-17.5%) might be because of the molecular size of the inserts: the MGMT P140K cDNA is only 600 bp and the MDR1-IRES-MGMT P140K construct more than 5 kb. Precisely because of the low effects of the combination vector with monotherapy it is noteworthy, that there was a chemoprotective effect of HR'SIN-MDR1-IRES-MGMT P140K transduced CD34 + cells with combination therapy (BCNU+doxorubicin or TMZ+ paclitaxel) with a drastic increase of MGMT-positive cells in contrast with BCNU or TMZ monotherapy. This suggests that under high-selective pressure (especially in combination with the MDR1 substrates doxorubicin or paclitaxel), the HR'SIN-MDR1-IRES-MGMT P140K transduced cells had a survival advantage compared with untransduced and HR'SIN-MGMT P140K transduced cells. Nevertheless, the transduction efficiency with our combination vector should be increased. As recently shown in a study about new protocols for the genetic modification of stem cells, effective tools might be stimulation for the CD34 + cells before transduction with higher cytokine concentrations and/or pre-treatment with the proteasome inhibitor MG-132. 54 In conclusion, transduction of cells with the HR'SIN-MDR1-IRES-MGMT P140K combination vector resulted in distinct chemoprotective effects, especially with regard to combination therapies. Regarding the risk of insertional mutagenesis, 55 the combination vector conveys the advantage of simultaneous protective effects of two drug-resistance genes, requiring one integration site. Another advantage of the combination vector is that transduced cells will surely contain both genes, in contrast with a simultaneous transduction of two single vectors each containing one gene. Consequently our results will help in improving combination chemotherapy regimens by reducing myelotoxic side effects and increasing the therapeutic efficacy.
Lentiviral overexpression of MDR1 and MGMT
P140K P Maier et al
Materials and methods
Drugs BCNU (Bristol-Myers Squibb, Munich, Germany) was solubilized in 100% ethanol, ACNU (Baxter, Unterschleiheim, Germany) in aqua dest. and TMZ (Essex pharma, Munich, Germany) in DMSO. All substances were dissolved directly before use. Stock solutions of the following chemicals were stored at À20 1C: O 6 -BG (Sigma-Aldrich, Munich, Germany) dissolved in DMSO; vincristine (GRY-Pharma, Kirchzarten, Germany) dissolved in 0.9% NaCl-solution. Paclitaxel (Bristol-Myers Squibb) and doxorubicin (Farmitalia Carlo Erba, Freiburg, Germany) were obtained as solutions.
Cell lines
The human myeloid leukemia cell line, HL60, was cultured in RPMI-1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (PAA, Pasching, Austria), penicillin (100 IU ml À1 ) (Invitrogen) and streptomycin (100 mg ml À1 ) (Invitrogen), at 37 1C and 5% CO 2 . The human fibrosarcoma cell line, HT1080, and the embryonic kidney cell line, 293T, were grown in DMEM (Invitrogen) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin under the same standard conditions. , the primers IRES-MGMT forward and MGMT reverse were used. The amplified sequences were checked by cycle sequencing using an ABI Prism Genetic Analyzer 310 (PE Applied Biosystems, Weiterstadt, Germany). The fragment of IRES-MGMT P140K was inserted via Bgl II and Xba I sites into pUC19, wherein the multiple cloning site was enlarged with the addition of a Not I and a Bgl II site between the BamH I and the Xba I sites. The coding sequence of MDR1 (taken from SF91m13, 56 using Not I and BamH I restriction sites) was placed in front of IRES-MGMT P140K with Not I and Bgl II (Bgl II is compatible to BamH I), resulting in pUC19-MDR1-IRES-MGMT
P140K
. Afterwards the fragment of MGMT P140K or MDR1-IRES-MGMT P140K was cloned into the lentiviral plasmid pHR'SIN-cPPT-SEW 32 via BamH I/ Xba I, replacing the coding sequence of eGFP (a second Xba I site behind the U3LTR was deleted in advance) resulting in the two plasmids pHR'SlN-MGMT P140K and pHR'SIN-MDR1-IRES-MGMT
. Cloning of the plasmid pHR'SIN-MDR1 was described previously. 57 In Figure 1a the schematic structure of the various lentiviral plasmids is shown. These lentiviral SIN-vectors contain the central polypurine tract sequence (cPPT), a promoter from spleen focus forming site virus and the woodchuck hepatitis virus post-transcriptional regulatory element. The connecting IRES element is EMCV based.
Production of lentiviral vectors
Lentiviral stocks were produced as described by Demaison et al. 32 293T cells (5 Â 10 6 ) in 100-mm tissue culture dishes were transfected with one of the lentiviral plasmids and two packaging plasmids pCMVDR8.91 and pMD.G using Metafectene (Biontex, Martinsried/ Planegg, Germany). After 24 h the medium was replaced by DMEM supplemented with 10% FCS and 10 mM sodium-butyrate (Sigma-Aldrich). About 10 h later the medium was replaced by serum-free DMEM. After an overnight cultivation virus-containing supernatants were collected. Lentiviral supernatants were cleared by filtration through a 0.45 mm pore-size filter (Millipore, Carrigtwohill, Ireland) and concentrated using a 100 000 MW cut-off Vivaspin filter (Sartorius, Goettingen, Germany). Aliquots were stored at À80 1C.
Viral titers were determined by flow cytometry after the transduction of HT1080 cells with serial dilutions of viral supernatant in the presence of 8 mg ml À1 polybrene (Sigma-Aldrich).
Transduction
The HL60 cells were transduced in the presence of polybrene (8 mg ml
À1
) at a multiplicity of infection of 1.5 or 3. 48 h later the medium was changed (polybrene-free), followed by selection with either vincristine (20 nM) after transduction with HR'SIN-MDR1 or HR'SIN-MDR1-IRES-MGMT P140K or BCNU (40 mM) after transduction with HR'SIN-MGMT P140K . Afterwards expression levels of the corresponding proteins were determined by flow cytometry (497%).
The CD34 + cells were prestimulated for 16-20 h at a density of 1 Â 10 6 cells ml À1 in IMDM (supplemented with 10% FCS) containing human stem cell factor (100 ng ml À1 ), Flt-3-ligand (100 ng ml
) and thrombopoietin (20 ng ml À1 ) (R&D systems, Wiesbaden, Germany). During the next 2 days cells were transduced three times at a multiplicity of infection of 10 in the presence of polybrene (8 mg ml
).
Flow cytometry (FACS)
The percentage of cells expressing MDR1 was determined by the Rh-123 efflux assay. 58 Briefly, cells were incubated with Rh-123 (Sigma-Aldrich) at a final 59 In brief, fixation and permeabilization was carried out with the Fix&Perm Cell Permeabilization kit (An der Grub GmbH, Kaumberg, Austria) according to the manufacturer's instructions. Cells were incubated overnight at 4 1C with the anti-MGMT antibody (1:30). Cells were then washed and incubated with a secondary phycoerythrin-conjugated goat anti-mouse antibody (Dako, Hamburg, Germany) for 1 h at 4 1C. Before measurement the cells were washed and resuspended in 200 ml staining medium (PBS, 4% FCS).
Acquisition was carried out on a FACSCalibur flow cytometer (Becton Dickinson).
RNA Isolation and cDNA Synthesis
The cells (3-5 Â 10 5 ) were harvested and total RNA was extracted and purified with the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription of 500 ng total RNA was carried out with TaqMan Reverse Transcription Reagents (PE Applied Biosystems). 0 . GAPDH (PE Applied Biosystems, VIC-MGB labeled) was used as reference gene. All PCR reactions were carried out in triplicates using an ABI Prism 7700 sequence detection system (PE Applied Biosystems) with the following thermocycling conditions: 50 1C for 2 min, 95 1C for 10 min and then 40 cycles of 15 s at 95 1C and 1 min at 60 1C. Quantification of the transcripts was made by the DDC t -method (User Bulletin #2, ABI PRISM 7700 sequence detection system).
Drug treatment and chemosensitivity assays
For the determination of MGMT P140K -mediated chemoresistance, cells were pretreated with O 6 -BG (20 mM) for 1 h, then the alkylating agent (BCNU, ACNU or TMZ) was added for 2 h at indicated concentrations. Thereafter, the cells were incubated in fresh medium containing O 6 -BG (20 mM) for another 21 h. Paclitaxel and doxorubicin were either added to cell suspension for 48 h (MTT-assay) or for 5 h (liquid culture). For combination therapy, treatment with the alkylating agent was done first. The following day cells were incubated with paclitaxel or doxorubicin, besides the procedure was the same as indicated for monotherapy.
The MTT assay was used to determine drug resistance of transduced HL60 cells. It is based on the ability of viable cells to cleave the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) to purple formazan crystals. In brief, 2 Â 10 4 cells in 100-ml culture medium were plated per well of 96-well plates. The cells were treated, as described above, in serial drug dilutions. After incubation for 48 h at 37 1C 15 ml per well of MTT-solution (5 mg ml À1 ) were added. Then the plates were incubated for another 4 h at 37 1C and afterwards 100 ml per well of 10% sodium dodecyl sulfate solution in 0.01 M hydrochloric acid were added. After overnight incubation at 37 1C the absorbance of the solubilized formazan crystals was measured (Multiskan Bichromatic, Labsystems, Helsinki, Finland). IC 50 values were calculated using the CalcuSyn Software (Biosoft, Cambridge, UK).
The chemoprotection of CD34 + cells was assayed by flow cytometry. Three days after transduction cells were seeded into 24-well plates at a concentration of 5 Â 10 4 /0.5 ml IMDM medium and were exposed to varying drug concentrations as described above. Afterwards the cells were kept in liquid culture for 12 days under myeloid-specific differentiation conditions (IMDM supplemented with 10% FCS, containing IL-1b, IL-3, IL-6, G-CSF, GM-CSF and SCF, each at a concentration of 10 ng ml
À1
; R&D Systems). Subsequently the proportions of MGMT or MDR1 expressing cells were determined by flow cytometry.
The liquid culture is required as human CD34 + cells endogenously express MDR1, which cannot be distinguished by FACS from the lentiviral MDR1 expression. After differentiation to myeloid cells the endogenous MDR1 expression is silenced, and therefore only transgenic MDR1 expression can be detected by Rh-123 assay at that time. 2 
Statistical analysis
Results are presented as means ± s.d. and represent normally three independent experiments (as indicated in figure legends). Data were analyzed with the statistical software R (R Development Core Team), using the nonparametric Wilcoxon's rank-sum test (un-paired). P-values less than or equal to 0.05 were designated as statistically significant and the evaluation is based on IC 50 values (MTT-assay) or the difference between treated and untreated fraction (flow cytometric analysis).
